Abstract: The present invention relates to a method, a device, and a program for calculating a brachytherapy plan, and a brachytherapy apparatus. The method comprises: a step in which a computer obtains the number of radiation irradiation spots on the basis of radiation irradiation information (a radiation irradiation spot number obtaining step (S200)); a step in which the computer obtains target area information from a body model of a patient generated on the basis of medical image data of the patient (a target area information obtaining step (S400)); and a therapy plan calculating step (S600) in which the computer calculates, on the basis of the radiation irradiation information and the target area information, the radiation irradiation spots to which radiation is irradiated and the time length of irradiation to each radiation irradiation spot.

Abstract: The present invention provides a triple fusion imaging device for sentinel lymphadenectomy for laparoscopic surgery including: a composite laparoscope for near infrared ray/gamma ray/visible ray acquisition configured to acquire triple images of a gamma ray from a gamma ray radioactive material injected to a diseased part, a visible ray, and a near infrared ray; an optical fiber configured to transmit the triple images acquired from the composite laparoscope; an optical source configured to generate a white light for acquiring a visible image through the optical fiber and a near infrared ray excitation light for acquiring a near infrared ray image by exciting a near infrared ray emitting fluorescence material at the disease part; an optical-to-electrical conversion module configured to separate individual images of the visible ray, near infrared ray and gamma ray from the triple images delivered through the optical fiber and then respectively convert the individual images to electrical signals; a matching uni

Abstract: A substance inhibiting the expression of CCND3 gene or PAK2 gene, the substance containing a nucleotide such as miR-4779, may be efficiently used for preventing or treating cancer. In addition, by screening the substance that inhibits the expression of CCND3 gene or PAK2 gene, a candidate substance for preventing or treating cancer may be selected.

Abstract: The present invention relates to a pharmaceutical composition for radioprotection or radiomitigation with respect to radiation-induced damage, the composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: The present invention relates to an artificial cartilage containing mesenchymal stem cell (MSC)-like dedifferentiated cells obtained by passage culturing costal chondrocytes, and a preparation process thereof.

Abstract: The present invention relates to a body insertable device having an outer body being bent; and an inner body positioned inside the outer body, having an accommodation space in which the resource soured is accommodated, and being capable of rotating inside the outer body, wherein a radiation emission direction is continuously adjusted by rotation of the inner body.

Abstract: A substance inhibiting the expression of CCND3 gene or PAK2 gene, the substance containing a nucleotide such as miR-4779, may be efficiently used for preventing or treating cancer. In addition, by screening the substance that inhibits the expression of CCND3 gene or PAK2 gene, a candidate substance for preventing or treating cancer may be selected.

Abstract: Provided are a conjugate including an EGFR inhibitor that enables treatment and diagnosis of epidermal growth factor receptor (EGFR)-overexpressing tumors including resistant tumors, a method that enables drug delivery treatment and diagnosis of EGFR-overexpressing tumors using the conjugate, and a method of preparing the conjugate.

Abstract: The present invention relates to a method for inhibiting an inflammatory response in chondrocytes, and dedifferentiation or destruction of chondrocytes by irradiating damaged chondrocytes with low-dose radiation, and a method of treating a disease of cartilage by irradiating damaged chondrocytes with low-dose radiation.

Abstract: The present invention relates to a pharmaceutical composition for treating a radiation- or drug-resistant cancer, containing an agent capable of inhibiting the expression of hepatoma-derived growth factor (HDGF)-related protein-3 (HRP-3), a method of treating a radiation- or drug-resistant cancer by administering the pharmaceutical composition, and the use of an HRP-3 inhibitor for preparing an agent for treating a radiation- or drug-resistant cancer. The use of the pharmaceutical composition of the present invention enables to treat a resistant cancer in combination with a conventional anticancer chemotherapy or radiotherapy. Accordingly, the pharmaceutical composition of the present invention can reduce both the costs for developing anticancer agents against resistant cancers and the costs for treating cancers in patients, thus being useful for the economic and effective treatment of resistant cancers.

Abstract: Provided are apparatuses and methods of resampling event data for quantitative improvement of a PET image, which acquire a quantitatively-improved new PET image by analyzing a storage format of list data prior to conversion into the PET image and nonparametrically resampling event data from the list data based on the analysis results to improve noise and statistical characteristics thereof. The quantitatively improved new PET image may be acquired by analyzing a storage format of list data constituting the PET image and nonparametrically resampling event data to improve noise and statistical characteristics thereof.

Abstract: The present invention relates to an artificial cartilage containing mesenchymal stem cell (MSC)-like dedifferentiated cells obtained by passage culturing costal chondrocytes, and a preparation process thereof.

Abstract: The present invention relates to an artificial cartilage containing mesenchymal stem cell (MSC)-like dedifferentiated cells obtained by passage culturing costal chondrocytes, and a preparation process thereof.

Abstract: Provided are a novel compound, in which a bombesin derivative known as having selectivity with respect to prostate cancer bonds with a ligand via aminomethyl galacturonic acid, a complex compound that covalently bonds with a radioactive isotope via the ligand of the novel compound, methods of preparing the compounds, and a nuclear-based molecular imaging agent including the complex compound.

Abstract: Disclosed are increased expression of ERp57, ERp57-STAT3 complex, and ERp57-STAT3-Mcl-1 in laryngeal cancer, especially in radioresistant laryngeal cancer and their regulations on radioresistance of laryngeal cancer. As such, the efficacy of radiotherapy can be enhanced by diagnosing prognosis in laryngeal cancer and radioresistance of laryngeal cancer. Furthermore, provided are a method of screening a therapeutic agent for laryngeal cancer including selecting a candidate drug that inhibits the expression of ERp57 or inactivates ERp57, and a therapeutic method for inhibiting or treating laryngeal cancer or radioresistant laryngeal cancer, thereby being useful in the treatment of laryngeal cancer.

Abstract: Provided is a composition for inducing tumor cell senescence and a method for inducing tumor cell senescence using the same. The composition can inhibit a PAPSS2 gene in a tumor cell to thereby induce senescence of the tumor cell, and if the composition is used concurrently with irradiation of the tumor cell, the composition can improve the sensitivity of the tumor cell to radiation.

Abstract: Disclosed is an anticancer supplement agent including a benzo[d]oxazole derivative as an effective ingredient. The benzo[d]oxazole derivative, which is a nuclear factor E2-related factor 2 (Nrf2) inhibitor, is capable of inhibiting activity of Nrf2 that induces an antioxidant enzyme to remove reactive oxygen species (ROS) that kills a cancer cell, thereby increasing production of ROS. Therefore, the benzo[d]oxazole derivative can be used as an anticancer supplement agent that shows therapeutic effects in anticancer agent therapy or radiation therapy, and in this regard, the benzo[d]oxazole derivative can overcome tolerance of the cancer cell to anticancer agent therapy or radiation therapy and enhance apoptotic effects on the cancer cell.

Abstract: Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof: wherein, in Formula I, —R1 is a C1-C3 alkoxy, ?O, or —OH, and —R2 is a 5- or 6-membered heteroaryl including 1 to 2 hetero atoms selected from nitrogen and oxygen, wherein a carbon of the 5- or 6-membered heteroaryl is optionally substituted with a C1-C3 alkyl a C1-C3 alkoxy, or hydroxy.

Abstract: A thin-layer chromatography type radiation detector includes a plurality of light-emitting members configured to generate visible light due to radiation, each of the light-emitting members including a scintillator having a surface filled with a reflector for reflecting the visible light, and are arranged in parallel to one another in a width direction, light sensors respectively coupled to one end portions of the plurality of light-emitting members and configured to measure a current generated due to the visible light generated by the plurality of light-emitting members, and an output port configured to sequentially output values of the current measured by the light sensors as digital signals.

Abstract: Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof: wherein, in Formula I, —R1 is a C1-C3 alkoxy, ?O, or —OH, and —R2 is a 5- or 6-membered heteroaryl including 1 to 2 hetero atoms selected from nitrogen and oxygen, wherein a carbon of the 5- or 6-membered heteroaryl is optionally substituted with a C1-C3 alkyl a C1-C3 alkoxy, or hydroxy.